North American Neuroendocrine Tumor Society

01/12/2026

January isn’t just the start of a new calendar year; it’s also one of the most active periods for research planning across academic medicine. Historically, Q1 is a peak time for finalizing NIH grant submissions, launching new study concepts, and opening clinical trial protocols, as investigators align fresh ideas with new funding cycles and institutional priorities.

For the NET community, this means that many of the studies, therapies, and biomarkers highlighted at future NANETS Symposia are being conceptualized right now, in early brainstorming meetings, protocol drafts, and cross-disciplinary collaborations. In that sense, the new year isn’t only about reflection; it’s about laying the groundwork for the next wave of discovery that will shape NET care in the years ahead. https://loom.ly/z0ff2dQ

01/08/2026

As we look ahead to 2026, the NET community reflects on a year of meaningful progress. At the 2025 NANETS Annual Multidisciplinary NET Medical Symposium, Dr. Simron Singh’s NET Year in Review highlighted advances across therapies, diagnostics, biomarkers, and clinical decision-making.

Pivotal trials expanded treatment options across NET subtypes, while targeted therapies and radioligand treatments showed broader and more durable impact. Biomarkers and imaging reinforced the move toward more precise, individualized care, and new data challenged long-held assumptions in surgery and liver-directed therapy. With updated guidelines, improving survival, and emerging topics like AI and GLP-1 receptor agonists, the field enters 2026 better equipped to translate discovery into patient impact.

01/06/2026

As we welcome 2026, the NANETS Board of Directors thanks our members, volunteers, staff, partners, and sponsors for making this community so strong. Your dedication drove meaningful progress in education, multidisciplinary care, advocacy, and research in 2025. We look ahead to 2026 with optimism and momentum and wish you a healthy, fulfilling New Year as we continue advancing care for patients with neuroendocrine tumors.

12/30/2025

We’re collecting responses for the “Why NENs?” Early-Career Survey, and we’re only about halfway to the number needed for meaningful, actionable data. If you’re early in your NET career, please take a few minutes to share what brought you into the field, what keeps you engaged, and the challenges you’re facing.

Your feedback directly shapes future programming, resources, and support for early-career members. Please complete the survey, and help us reach full participation by sharing it with colleagues and trainees.

Your voice matters, and it only takes a few minutes to make an impact: https://loom.ly/SwXuAt8

12/22/2025

As planning begins for the 2026 Multidisciplinary NET Medical Symposium in Las Vegas, we continue to welcome topic and session ideas from the NANETS community. If you have emerging research, clinical challenges, case-based concepts, or multidisciplinary themes you believe should be highlighted next year, we encourage you to submit your suggestions. Your input helps ensure the program reflects the evolving needs of the field and continues to deliver timely, relevant, and impactful education for the NET community.

Submission Deadline: Friday, January 9, 2026

Add your ideas, share your expertise, and help us build a dynamic and forward-thinking program for 2026.

12/19/2025

This episode of NETCast features a panel on NET patient advocacy. They explore why advocacy is critical for this rare cancer, discussing challenges patients face at diagnosis, the importance of education and resources, research funding obstacles, and political advocacy efforts. The panel emphasizes that patients should be active participants in advocacy—whether through contacting reprsentatives, supporting research organizations, or engaging in educational initiatives—to make this "invisible" disease visible and drive meaningful change in treatment and outcomes.

🎙️ Listen now: https://loom.ly/vUzPWdU

12/16/2025

A new patient–advocate–clinician collaboration is reshaping how the NET community approaches treatment sequencing in GEP-NETs.

The newly published review, Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective, centers the lived experiences, values, and priorities of patients as a critical part of care planning.

We’re proud to see insights from NANETS members Dr. Mark Lewis, Jessica Thomas, and Lisa Yen, NP, NBC-HWC reflected in this meaningful work, highlighting the importance of shared decision-making and patient voice in advancing NET care.

📄 Read the review: https://loom.ly/0WTOklc

12/11/2025

Make your voice heard in cancer care! With the ACT Network, you can send pre-drafted messages to lawmakers, follow key legislation, and stay up to date on the issues that matter most.

Get started: https://loom.ly/Ag8C-OI

Write a letter to your lawmaker today!

12/08/2025

Join colleagues worldwide for the 2025 ENETS–NANETS Virtual NET Tumor Board on December 10, 12:00–1:30 PM EST. This year’s session covers precision therapies and emerging strategies in NEN care, featuring real-world pancreatic and small bowel NET cases presented by experts from both societies.

The multidisciplinary panel will discuss treatment sequencing, biomarkers, immunotherapy, and the evolving role of theranostics.

Free for all healthcare professionals, registration required: https://loom.ly/V9OS-js

This webinar is part of ENETS’ ongoing educational collaboration with the North American Neuroendocrine Tumor Society (NANETS), supporting international dialogue and shared learning in NET care.

12/05/2025

This quarter’s APP/AHP SIG meeting features a dynamic panel on the expanding role of APPs and AHPs in radiopharmaceutical care, a rapidly growing area in NET treatment.

Hear insights from clinicians across leading centers, including Vanderbilt, Mayo Clinic, University of Utah Health, and Moffitt Cancer Center, who are shaping this evolving field.

Don’t miss the conversation on advancing patient care, improving workflows, and strengthening multidisciplinary approaches.

Register today: https://loom.ly/NnCPXFI

12/03/2025

NANETS is proud to honor Dr. Samantha Greenberg, PhD, MS, MPH, CGC, as the 2025 Distinguished APP/AHP Award recipient. This award recognizes her exceptional leadership, impactful scholarship, and unwavering dedication to improving care for patients with hereditary neuroendocrine tumor (NET) syndromes.

A nationally respected genetic counselor and educator, Dr. Greenberg has advanced evidence-based care for patients and families facing complex hereditary conditions, while championing the vital role of genetics across the NET community.

11/26/2025

Patients, caregivers, and healthcare professionals are invited to take part in SCAN 2025 — the Survey of Challenges in Access for Diagnostics and Treatment for NET Patients.

Available in 15 languages, this global survey gathers vital insights to improve access to diagnosis, treatment, and care worldwide.

🗓️ Share your voice by November 30, 2025.

Take the survey today: https://loom.ly/wiiQVYY